ProQR Therapeutics has nominated Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors. With over 20 years of experience in global drug development, Dr. Hinsch Gylvin’s expertise is expected to enhance ProQR’s strategic growth and pipeline advancement. Her nomination will be presented for shareholder approval at the upcoming Annual General Meeting. ProQR is known for its innovative Axiomer™ RNA editing technology aimed at creating transformative RNA therapies for various diseases.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.manilatimes.net/2026/04/30/tmt-newswire/globenewswire/proqr-announces-nomination-of-dr-lykke-hinsch-gylvin-to-its-board-of-directors/2332666
